New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Subscribe To Our Newsletter & Stay Updated
